Table 2. Clinical and laboratory characteristics of the B-CLL patients.

Pt.#	Therapy	%CD38+ cells†	%ZAP-70+	Cytogenetic abnormalities*	IgVH status	TP53 status	IC50 Ibrutinib (μM)
1	Untreated	neg	neg	del13q	mut	wild-type	14.6
2	Ibrutinib	neg	neg	del11q, del13q	unmut	muta	11
3	Untreated	neg	neg	trisomy 12	mut	wild-type	0.1
4	Untreated	neg	neg	neg	mut	wild-type	14.4
5	Untreated	neg	neg	neg	mut	wild-type	12.3
6	Ibrutinib	pos	na	del11q, del13q	unmut	mutb	17.7
7	Untreated	pos	pos	del13q	unmut	wild-type	10.2
8	Untreated	neg	neg	del13q	mut	wild-type	12.5
9	R-Benda	pos	neg	del13q	unmut	wild-type	11.2
10	Untreated	neg	neg	na	mut	wild-type	5.3
11	Untreated	pos	neg	del13q	mut	wild-type	11.8
12	Ibrutinib	neg	neg	del11q, del17p, del13q	unmut	mutc	4.4
13	Chl	pos	neg	neg	unmut	wild-type	3.1
14	Untreated	neg	na	neg	na	wild-type	35.9
15	Untreated	neg	neg	del13q	mut	wild-type	5.2
16	R-Benda	neg	neg	del13q	mut	wild-type	2.5
17	FC, FCR, R-Benda	neg	neg	del11q, del13q	na	wild-type	8.1
18	Untreated	pos	na	trisomy 12	mut	wild-type	10.5
19	Untreated	pos	na	trisomy 12	na	na	7.1
20	Untreated	neg	neg	neg	mut	wild-type	2.9
21	Untreated	neg	na	del13q	na	na	15
22	Ibrutinib	neg	na	del13q	unmut	wild-type	17.6

Pt., patient; R-Benda, Rituximab-Bendamustine; Chl, Chlorambucil; FC, Fludarabine-Chlorambucil; FCR, Fludarabine-Chlorambucil-Rituximab; neg, negative; pos, positive; na, not available; mut, mutated; unmut, unmutated.

^†Results obtained in cytometric assays, using a CD38 cutoff of 30%.

^*Cytogenetic abnormalities were evaluated by fluorescence in situ hybridization (FISH) analysis.

^ac.394A>G:p.K132E;

^bc.644G>A:p.S215N;

^cc.770T>C:p.L257P.